▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Shannon Jones

TMFLilDebbie

Recent Articles by Shannon Jones

cover_IF

Feb 7, 2020 by Shannon Jones

3 Biotech Companies Analyzed

We examine three biotech companies' past performances and future outlooks.

cover_IF

Jul 19, 2019 by Shannon Jones

Like Vanguard for Healthcare Costs: An Interview With HealthEquity CEO John Kessler

HealthEquity's CEO explains how the company makes money while helping people tackle healthcare savings.

cover_IF

Jul 2, 2019 by Shannon Jones, Jason Moser, Dylan Lewis, and Nicholas Sciple

Bearish Signs and Antitrust Tensions

The Industry Focus hosts gather round the table to talk about (potentially) impending (short-term) doom for the market and big tech.

cover_IF

Jun 12, 2019 by Shannon Jones and Brian Feroldi

The Fastest-Growing Healthcare Company You've Never Heard Of

This medical device maker is growing rapidly and has already treated its investors to huge gains. Here's why Wall Street is so excited about where this company is heading.

GettyImages-923244300

Jun 5, 2018 by Shannon Jones

2018 ASCO Conference Roundup

All your Motley Fool coverage of the 2018 ASCO Conference in one place.

IF_healthcare

Apr 26, 2018 by Shannon Jones

A Promising Step for Medical Marijuana

Medical marijuana enthusiasts, get hyped -- GW Pharma’s advisory committee meeting results could mean huge things for the industry.

IF_healthcare

Apr 12, 2018 by Shannon Jones

Why One Drug Flop Tanked Incyte's Stock

Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.

drugs-money_large

Aug 7, 2017 by Shannon Jones

These 3 Biotechs Just Crushed Analyst Expectations

But before you invest in any of them, you should read this.

Scientists

Jul 25, 2017 by Shannon Jones

3 Key Things Every CAR-T Investor Should Watch

The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn't mean CAR-T stocks are out of the woods just yet.

Jun 21, 2016 by Shannon Jones

3 Ways This $30 Billion Market Is Bristol's for the Taking

How this "Big Pharma" is revolutionizing the fight against cancer and well-positioned for long-term growth.

Apr 30, 2016 by Shannon Jones

3 Key Pipeline Developments for Gilead Investors to Watch

Forget Hepatitis C -- here are 3 key developments investors should keep on their radars in 2016.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services